title: IL-21 in cancer immunotherapy: At the right place at the right time.
abstract: Interleukin-21 (IL-21) has been described as a potent stimulator of antitumor T-cell immunity, but also of autoimmune reactions and oncogenesis. Antigen presenting cells genetically modified to release IL-21 allow for the expansion of tumor-specific T cells exhibiting favorable effector and growth characteristics and a minimal risk of detrimental side effects.
authors.affiliation: Department of Medical Oncology; VU University Medical Center; Cancer Center Amsterdam; Amsterdam, the Netherlands.
authors.forename: Saskia Jam
authors.initials: SJ
authors.lastname: Santegoets
authors.forename: Annelies W
authors.initials: AW
authors.lastname: Turksma
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Powell
authors.forename: Erik
authors.initials: E
authors.lastname: Hooijberg
authors.forename: Tanja D
authors.initials: TD
authors.lastname: de Gruijl
keywords: DC vaccination; IL-21; adoptive cell transfer; antigen presenting cell; common gamma-chain cytokine receptor family
references.citation: Cancer Immunol Immunother. 2013 Apr;62(4):727-36
references.pmid: 23207483
references.citation: Hum Immunol. 2013 May;74(5):506-13
references.pmid: 23376456
references.citation: Nature. 2012 Nov 8;491(7423):264-8
references.pmid: 23064231
references.citation: J Transl Med. 2013 Feb 12;11:37
references.pmid: 23402380
references.citation: Sci Transl Med. 2013 Feb 27;5(174):174ra27
references.pmid: 23447018
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):6125-36
references.pmid: 18829491
references.citation: Oncoimmunology. 2012 May 1;1(3):351-354
references.pmid: 22737612
references.citation: J Clin Oncol. 2012 Sep 20;30(27):3396-401
references.pmid: 22915661
references.citation: Nat Rev Cancer. 2012 Oct;12(10):671-84
references.pmid: 22996603
references.citation: Cytokine. 2013 Feb;61(2):656-63
references.pmid: 23312859